



## Modern Adjuvants and Their Roles in Vaccine Development

Guest Editor:

### Dr. Xinyuan Chen

Department of Biomedical and  
Pharmaceutical Sciences,  
University of Rhode Island,  
Kingston, RI 02881, USA

Deadline for manuscript  
submissions:

**20 February 2025**

### Message from the Guest Editor

Due to the uniqueness of each disease and the specific types of immune responses to be modulated, various kinds of adjuvants are needed to induce optimal immune responses against a particular disease. Vaccine adjuvants may also need to be tailored for use in different age groups due to the age-related differential immune responses to vaccines. In the past, adjuvant development has mainly relied on empirical experience, and only a few adjuvants have been approved for human use since the first (Alum) was discovered over 90 years ago. Significant advances have been made in the last three decades in understanding how adjuvants work. Modern techniques, such as high-throughput screening and in-silico screening, have also been used to discover novel adjuvants for human use. The last two decades have also seen increased investment in novel adjuvant development. These efforts are expected to accelerate novel adjuvant discovery and development. This Special Issue welcomes submissions of adjuvant discovery and development in diverse types of vaccines (e.g., subunit, mRNA-based) against infectious diseases, cancer, or immune-mediated diseases.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)